Ono Pharmaceutical (OPHLF) Stock Price, News & Analysis

Company Overview

Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and commercialization of prescription medicines. The company focuses primarily on oncology, immunology, neurology and other specialty therapeutic areas, with an emphasis on discovering treatments for diseases with significant unmet medical needs.

Ono’s best-known product is Opdivo (nivolumab), an immuno-oncology medicine developed in collaboration with Bristol Myers Squibb and approved for multiple cancer indications in various markets. The company also markets and develops additional medicines through its own research programs and collaborations with global pharmaceutical and biotechnology companies.

Founded in Osaka in 1717 as a pharmaceutical wholesaler, Ono has evolved into a research-based drug manufacturer with operations and commercial activities in Japan and international markets. Its products are distributed globally through subsidiaries and strategic partnerships. The company is headquartered in Osaka, Japan, and is led by President and Chief Executive Officer Gyo Sagara.

Key Stats

• Today's Range: $14.95 to $14.95
• 50-Day Range: $13.67 to $16.50
• 52-Week Range: $11.08 to $18.67
• Volume: N/A
• Average Volume: 3,129 shs
• Market Capitalization: $7.03 billion
• P/E Ratio: 14.24
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Ono Pharmaceutical Stock Analysis - MarketRank™

Ono Pharmaceutical scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Ono Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ono Pharmaceutical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Ono Pharmaceutical is 14.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ono Pharmaceutical is 14.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.35.

Price to Book Value per Share Ratio

Ono Pharmaceutical has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of Ono Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Ono Pharmaceutical has a short interest ratio ("days to cover") of 277.34, which indicates bearish sentiment.

Change versus previous month

Short interest in Ono Pharmaceutical has recently decreased by 17.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ono Pharmaceutical does not currently pay a dividend.

Dividend Growth

Ono Pharmaceutical does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.31

News Sentiment

Ono Pharmaceutical has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Ono Pharmaceutical this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ono Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

Ono Pharmaceutical has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/02/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:OPHLF
• CIK: 940821
• Web: www.ono.co.jp
• Phone: (166) 263-5670
• Fax: 816-6263-2950
• Employees: 4,206
• Year Founded: 1717

Profitability

• EPS (Trailing Twelve Months): $1.05
• Trailing P/E Ratio: 14.24
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $436.04 million
• Net Margins: 15.02%
• Pretax Margin: 17.96%
• Return on Equity: 9.77%
• Return on Assets: 7.63%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 3.28
• Quick Ratio: 2.86

Sales & Book Value

• Annual Sales: $3.43 billion
• Price / Sales: 2.05
• Cash Flow: $1.49 per share
• Price / Cash Flow: 10.04
• Book Value: $11.39 per share
• Price / Book: 1.31

Miscellaneous

• Outstanding Shares: 469,910,000
• Free Float: N/A
• Market Cap: $7.03 billion
• Optionable: Not Optionable
• Beta: 0.38